Treatment of depressive symptoms in patients with schizophrenia: A randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone

International Clinical Psychopharmacology

Volumn 30, Issue 1, 2015, Pages 14-22

  Kasper, Siegfried ^a   Montagnani, Gino ^b   Trespi, Graziella ^b   Di Fiorino, Mario ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ASTRAZENECA   (United Kingdom)

^c Versilia Hospital   (Italy)

Author keywords

Atypical antipsychotic; Depressive symptoms; Extended release quetiapine; Negative symptoms; Risperidone; Schizophrenia

Indexed keywords

PROLACTIN; QUETIAPINE; RISPERIDONE; DELAYED RELEASE FORMULATION; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; ASTHENIA; CALGARY DEPRESSION SCALE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HAMILTON SCALE; HUMAN; HUMAN CELL; HYPERPROLACTINEMIA; INSOMNIA; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SCHIZOPHRENIA; SEDATION; SOMNOLENCE; WEIGHT GAIN; XEROSTOMIA; CLINICAL TRIAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; ITALY; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TIME; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DEPRESSION; DIBENZOTHIAZEPINES; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84918808377     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000053     Document Type: Article

References (36)

1. Addington D, Addington J, Schissel B (1990). A depression rating scale for schizophrenics. Schizophr Res 3:247-251.
2. Addington D, Addington J, Maticka-Tyndale E, Joyce J (1992). Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 6:201-208.
3. Addington D, Addington J, Patten S (1998). Depression in people with firstepisode schizophrenia. Br J Psychiatry Suppl 172:90-92.
4. Addington DE,M ohamed S,Rosenheck RA,Davis SM,Stroup TS,McEvoy JP,et al. (2011), Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia, J Clin Ps ychiatry, 72, 75-80.
5. Arvanitis LA, Miller BG (1997). Multiple fixed doses of " Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 42:233-246.
6. AstraZeneca UK Limited (2012). Seroquel XL summary of product characteristics (UK), revised 2012. Available at: http://www.medicines.org.uk/EMC/medi cine/21175/SPC/. [Accessed 1 February 2014].
7. Buckley PF (2004). Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin 20:1357-1363.
8. Canuso CM, Dirks B, Carothers J , Kosik-Gonzalez C, Bossie CA, Zhu Y, et al. (2009). Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 166:691-701.
9. Chemerinski E, Bowie C, Anderson H, Harvey PD (2008). Depression in schizophrenia: methodological artifact or distinct feature of the illness? J Neuropsychiatry Clin Neurosci 20:43 1-440.
10. Collins AA, Remington G, Coulter K, Birkett K (1996). Depression in schizophrenia: a comparison of three measures. Schizophr Res 20:205-209.
11. Conley RR, Ascher-Svanum H, Zh u B, Faries DE, Kinon BJ (2007). The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res 90:186-197.
12. De Nayer A,Windhager E, Irmansyah, Larmo I, Li ndenbauer B, Rittmannsberger H, et al. (2003). Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiatry Clin Pract 7:59-66.
13. Di Fiorino M, Montagnani G, Trespi G, Kasper S (2014). Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study. Int Clin Psychopharmacol 29:166-176.
14. Dollfus S, Olivier V, Chabot B, Déal C, Perrin E (2005). Olanzapine versus risperidone in the treatment of post-psychotic dep ression in schizophrenic patients. Schizophr Res 78:157-159.
15. Emsley RA, Buckley P, Jones AM, Greenwood MR (2003). Differential effect of quetiapine on depressive symptoms in patients with partially resp onsive schizophrenia. J Psychopharmacol 17:210-215.
16. Farah A (2005). Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry 7:268-274.
17. Goldstein JM, Christ oph G, Grimm S, Liu J, Widzowski D, Brecher M (2007). Quetiapine's antidepressant properties: direct and indirect pharmacologic actions on norepinephrine and serotonin receptors. Eur Neuropsychopharmacol 17 (Suppl 4):S40 1.
18. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. (2012). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: upd ate 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13:318-378.
19. Janssen-Cilag Ltd (2006). Risperdal Quicklet orodispersible tablets. Summary of product ch aracteristics (UK), revised 2006. Available at: http://www.janssencilag. co.uk/content/extended-products/www.janssen-cilag.uk/pdf/Risperdal- SPC.pdf [Accessed 13 February 2014].
20. Jensen NH, Rodriguiz RM, Caron MG, We tsel WC, Rothman RB, Roth BL (2008). N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33: 2303-2312.
21. Kasper S (2004). Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress Anxiety 20:44-47.
22. Kjelby E, Jørgensen HA , Kroken RA, Lø berg EM, Johnsen E (2011). Antidepressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial. BMC Psychiatry 11:145.
23. Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J (1993). Depression in first-episode schizophrenia. Am J Psychiatry 150:1643-1648.
24. Lee KU, Jeon YW, Lee HK, Jun TY (2009). Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia. Hum Psychopharmacol 24:447-452.
25. Majadas S,Olivares J,Galan J,Diez T, 2012, Prevalence of depression and its relationship wi th other clinical characteristics in a sample of patients with stable schizophrenia, Compr Psychiatry, 53, 145-151.
26. Marengo J, Harrow M, Herbener ES, Sands J (2000). A prospective longitudinal 10-year study of schizophrenia's three major factors and depression. Psychiatry Res 97:61-77.
27. Mullen J, Jibson MD, Sweitzer D (2001). A comparison of the relative safety, efficacy, and tolerability of quetiapine and r isperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 23:1839-1854.
28. Nyberg S, Widzowski D (2010). Translational pharmacology of quetiapine and norquetiapine: preclinical findings support multifunctional psychotropic properties. Eur Psychiatry 25 (Suppl 1):1446 Abstract PW01-27.
29. Roth BL, Sheffler D, Potkin SG (2003). Atypical antipsychotic drug actions: unitary or multiple mechanisms for ?atypicality'? Clin Neurosci Res 3:108-117.
30. Sands JR, Harrow M (1999). Depression during the longitudinal course of schizophrenia. Schizophr Bull 25:157-171.
31. Schennach-Wolff R, Obermeier M, Seemüller F, Jä ger M, Messer T, Laux G, et al. (2011). Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale. A cta Psychiatr Scand 123:228-238.
32. Seeman P (2002). Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27-38.
33. Siris S, Bench C (2003). Depression and schizophrenia. In: Hirsch S, Weinberger D, editors. Schizophrenia. Oxford, UK: Blackwell 142-167.
34. Skodl ar B (2009). Three different meanings of depression in schizophrenia. A phenomenological perspective. Psychiatr Danub 21 (Suppl 1):88-92.
35. Small JG, Kolar MC, Kellams JJ (2004). Quetiapine in schizophrenia: onset of action within the first week of treatment. Curr Med Res Opin 20:1017-1023.
36. Suttajit S, Pilakanta S (2010). Impact of depression and social support on nonadherence to antipsychotic drugs in persons with schi zophrenia in Thailand. Patient Prefer Adherence 4:363-368.